SCHEMBL2275883

SCHEMBL2275883

CCOC(=O)Cc1cc(Oc2ccc(N)cc2CSCC(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.35
CETP P11597 2/20 0.34
MAPT P10636 3/20 0.33
LMNA P02545 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
SHMT2 P34897 1/20 0.32
SCN9A Q15858 1/20 0.31
FFAR1 O14842 1/20 0.31
PPARA Q07869 3/20 0.31
PPARG P37231 2/20 0.31
PPIB P23284 1/20 0.31
PPIA P62937 1/20 0.31
PPID Q08752 1/20 0.31
PPIG Q13427 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280519 0.87 CETP (0.37) MAPK1CETPMAPTLMNAATM
SCHEMBL350170 0.86 LMNA (0.37) CETPMAPTLMNAALDH1A1HPGD
SCHEMBL13521855 0.86 MAPK1 (0.38) MAPK1CETPMAPTLMNAATM
SCHEMBL348738 0.85 CYP3A4 (0.42) MAPTLMNAALDH1A1SLC6A4
SCHEMBL349505 0.81 CYP3A4 (0.41) MAPK1MAPTLMNAATML3MBTL1
SCHEMBL2282210 0.81 MAPK1 (0.36) MAPK1MAPTL3MBTL1ALDH1A1HPGD
SCHEMBL348080 0.80 LMNA (0.35) MAPTLMNAALDH1A1HTR2ASLC6A4
SCHEMBL2275749 0.76 PTGDR2 (0.41) CETPFFAR1PPARAPPARD
SCHEMBL1643581 0.75 SLC6A4 (0.44) CETPMAPTATMRXRARXRB
SCHEMBL1645250 0.75 SLC6A4 (0.44) MAPK1MAPTLMNAATMRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 MAPK1 2947/4885CETP 3511/4885MAPT 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.